Clinical trials: Atezolizumab
Non-Hodgkins Lymphoma
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This is an open-label, single arm, multicenter, dose finding, Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general…
- Trial name
- NCT03533283
- Testing
- Glofitamab, Atezolizumab, Obinutuzumab
- Where
- 20 sites in United States, Belgium and 5 more
- Volunteers
- 211 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung, Immunotherapy
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
Immunotherapy is now a standard of care for first-line and eventually salvage therapy in patients with stage IV NSCLC and as adjuvant after RT-CT for stage III NSCLC.
- Trial name
- NCT04465942
- Testing
- (chemo)immunotherapy
- Where
- 5 sites in Belgium
- Volunteers
- 300 people
- Sponsor
- European Lung Cancer Working Party
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
This is a multicenter, randomized, controlled, open-label study comparing perioperative atezolizumab with FLOT chemotherapy versus FLOT alone in patients with locally advanced, operable adenocarcinoma of the stomach or GEJ with…
- Trial name
- DANTE (NCT03421288)
- Testing
- Atezolizumab, 5-Fluorouracil, Calciumfolinat
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 677 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Non-Small Cell Lung Cancer
ITTACA (Immunotherapy Time Teller for Advanced Lung Cancer)
Immunotherapy is a relatively new treatment that uses patients' own immune systems to fight diseases, particularly cancers. Recent studies suggest that the effectiveness of immunotherapy in cancer treatment may depend on the time…
- Trial name
- ITTACA (NCT07661251)
- Volunteers
- 60 people
- Sponsor
- Laura Longshaw
HCC
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
This study will evaluate the efficacy and safety of TACE combined with atezolizumab + bevacizumab in the treatment of unresectable hepatocellular carcinoma, and the treatment patterns of the combination regimen
- Trial name
- CHANCE023 (NCT06024252)
- Testing
- TACE
- Volunteers
- 200 people
- Sponsor
- Zhongda Hospital
Castrate-Resistant Prostate Cancer
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
This study is designed to assess the safety and tolerability of atezolizumab when given in combination with radium-223 dichloride in participants with metastatic CRPC who have progressed after treatment with an androgen pathway…
- Trial name
- NCT02814669
- Testing
- Atezolizumab, Radium-223 Dichloride
- Where
- 17 sites in United States
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as detailed below. Each study cohort will be analyzed separately.
- Trial name
- NCT03520686
- Testing
- NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab, NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel
- Where
- 31 sites in United States
- Volunteers
- 102 people
- Sponsor
- ImmunityBio, Inc.
Solid Tumor, Rhabdomyosarcoma
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
- Trial name
- NCT04796012
- Testing
- Atezolizumab, Vincristine, Irinotecan
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of Texas Southwestern Medical Center
Urothelial Carcinoma
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
FORT-2 is designed to evaluate safety, efficacy, RP2D and PK of rogaratinib in combination with atezolizumab in patients with untreated FGFR-positive urothelial carcinoma.
- Trial name
- FORT-2 (NCT03473756)
- Testing
- Rogaratinib (BAY1163877), Atezolizumab
- Where
- 30 sites in United States, Austria and 6 more
- Volunteers
- 37 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease.
- Trial name
- LIVIGNO-2 (NCT06109272)
- Testing
- Livmoniplimab, Budigalimab, Durvalumab
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 89 people
- Sponsor
- AbbVie
Colorectal Cancer
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
CO40939 is a Phase Ib, open-label, multicenter, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of cibisatamab in combination with atezolizumab administered after pretreatment with…
- Trial name
- NCT03866239
- Testing
- Obinutuzumab, Atezolizumab, Cibisatamab
- Where
- 13 sites in United States, Denmark and 2 more
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Neoplasm
Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer
Locoregional failure remains the principal mode of mortality in head and neck squamous cell carcinoma (HNSCC) treated with conventional chemoradiation therapy.
- Trial name
- DEHART (NCT04477759)
- Testing
- 50 Gy Radiation Therapy, 55 Gy Radiation Therapy, 60 Gy Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical College of Wisconsin
Urothelial Carcinoma
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to provide atezolizumab access to participants with locally advanced or metastatic urothelial carcinoma that has progressed on, or is…
- Trial name
- NCT02589717
- Testing
- Atezolizumab [TECENTRIQ]
- Where
- 40 sites in United States
- Sponsor
- Genentech, Inc.
Cancer, Lung Cancer
Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors
The recent introduction of anti-PD-1 (nivolumab and pembrolizumab) and anti- PD-L1 (atezolizumab, durvalumab, avelumab) immune checkpoint inhibitors revolutionized oncological guidelines.
- Conditions
- Cancer, Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- ICI-DISCOVER (NCT04268368)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Università Politecnica delle Marche
Pleural Mesothelioma Malignant Advanced
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma.
- Trial name
- BEAT-meso (NCT03762018)
- Testing
- Carboplatin, Pemetrexed, Bevacizumab
- Where
- 42 sites in Belgium, France and 4 more
- Volunteers
- 400 people
- Sponsor
- ETOP IBCSG Partners Foundation
Non-Small Cell Lung Cancer
The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients
This study is designed to evaluate the predicted potential of quantitative T cell repertoire (TCR) of T cell receptor chains using next-generation sequencing (NGS) in the treatment of the anti-programmed death-ligand 1 (PD-L1)…
- Trial name
- NCT03228368
- Testing
- Atezolizumab (MPDL3280A)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Squamous Cell Carcinoma of the Head and Neck
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT05459129
- Testing
- Atezolizumab, Tiragolumab, Carboplatin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
This early phase I trial studies the side effects and feasibility of cryoablation, atezolizumab, and nab-paclitaxel in treating patients with triple negative breast cancer that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04249167
- Testing
- Atezolizumab, Cryosurgery, Nab-paclitaxel
- Sponsor
- Mayo Clinic
Recurrent Non-Small Cell Lung Cancer
Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.
- Trial name
- NCT02919449
- Testing
- MV-NIS, Atezolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vyriad, Inc.
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
This phase I trial studies the side effects and best dose of COH06 with or without atezolizumab in patients with non-small cell lung cancer previously treated with PD-1 and/or PD-L1 immune checkpoint inhibitors that has spread to…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma
- Trial name
- NCT05334329
- Testing
- Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Irvine